Long Term Follow Up KET-PD

StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Enrolling by Invitation → Completed Show 5 more changesShow less
    • Final enrollment: 49 participants (planned 40)
    • Primary completion date changed from estimate of Dec 21, 2025 to Mar 16, 2026
    • Study completion date changed from estimate of Dec 21, 2025 to Mar 26, 2026
    • Secondary endpoints: details revised at 3 of 7 entries
    • Collaborators: details revised at 1 of 2 entries
  2. Primary completion date: Feb 2025 to Dec 21, 2025
    • Study completion date: Dec 2025 to Dec 21, 2025
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Yale University
490 trials monitored
See 31 trials at risk
Depression
3,069 trials monitored
See 170 trials at risk
Parkinson's Disease
1,462 trials monitored
See 71 trials at risk
The purpose of this study is to examine a) the longer-term effects of ketamine for treating depression in Parkinson's disease (PD) and b) the effects of CBT on maintaining the effects of ketamine.
Trial Details
NCT Number NCT06164756
Lead Sponsor Yale University
Collaborators: Michael J. Fox Foundation for Parkinson's Research, Yale School of Medicine Center for Brain Mind Health
Conditions
(from sponsor)		 Parkinson's Disease, Depression
Related terms Depression, Parkinson Disease
Enrollment 49 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov